Wire · opportunities
Teva wins FDA approval for monthly schizophrenia injection Weltruza
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 October 2026 · Fusion42 review
Teva received FDA approval for Weltruza, a once-monthly injectable treatment for adults with schizophrenia, leveraging Medincell's long-acting injection technology to improve treatment adherence. The drug launch is expected in the US within weeks and could trigger up to $112 million in milestone payments for Medincell.
This Wire brief sits within Fusion42's coverage of Medtech, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
You have a new potential entry point in US psychiatric treatment with monthly injectable olanzapine now approved; mental health therapeutics providers should prepare to integrate long-acting formulations to boost patient adherence.
◆ Coverage
14 sources · first reported 9 Oct 2026 · latest 10 Oct 2026
◆ Topics